首頁 > 市場調查報告書 > 製藥

生物製劑分子標靶治療學

市場調查報告書

商品編碼

2069646

抗體藥物複合體(ADC) 市場：按產品類型、目標抗原、有效載荷/技術、連接子類型、適應症和最終用戶分類 - 市場規模、行業動態、機會分析和預測 (2026–2035)

Antibody-Drug Conjugate Market: By Product, Target Antigen, Payload / Technology, Linker Type, Indication, End User - Market Size, Industry Dynamics, Opportunity Analysis And Forecast For 2026-2035

出版日期: 2026年06月12日 | 出版商:

Astute Analytica | 英文 280 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

全球抗體藥物複合體（ADC）市場正經歷顯著成長，反映出癌症治療領域正迅速轉向更精準、更具標靶性的治療方法。預計2025年市場規模約142.3億美元，2035年將達到約453.9億美元。這一成長意味著2026年至2035年預測期間的複合年成長率（CAGR）將達到12.30%，凸顯了ADC在全球醫療系統中持續強勁的成長動能。

這一強勁的成長動能主要得益於精準腫瘤學的廣泛發展，精準腫瘤學強調使用生物目標療法，旨在以高特異性攻擊癌細胞，同時最大限度地減少對健康組織的損傷。抗體藥物偶聯物（ADC）已成為此框架下最有前景的治療方法之一，它結合了單株抗體的靶向精準性和細胞毒性有效載荷的強效細胞毒性。這種雙重作用機制顯著改善了多種癌症的治療效果，擴大了臨床接受度，並日益被納入標準腫瘤治療方案。

顯著的市場趨勢

抗體藥物複合體（ADC）市場的競爭格局日益受到大規模併購和戰略許可協議的影響，反映出各公司在下一代癌症療法領域爭奪主導的激烈競爭。隨著對高標靶癌症治療方法的需求持續成長，領先的製藥公司正積極投資ADC平台，以加強其癌症治療產品線，拓展技術能力，並確保獲得商業性驗證的資產。

該領域最重大的交易之一是輝瑞以約430億美元收購Sigen。這項開創性交易的驅動力在於輝瑞的策略目標，即加強其在腫瘤領域的地位，並獲得Sigen的開創性ADC技術和成熟的商業產品組合。

同樣，艾伯維(AbbVie)斥資約101億美元收購Immunogen，這是一項重大的策略舉措。此次收購使艾伯維獲得了在卵巢癌治療領域的關鍵資產—抗體偶聯藥物Elahele。另一筆引人注目的交易是強生(Johnson & Johnson)以約20億美元收購Ambreex BioPharma。

除了收購之外，中國正崛起為全球抗體藥物聯合體（ADC）領域併購和授權活動的重要力量。 2024年，中國生物製藥公司簽署了創紀錄的94項創新藥物許可協議，其中癌症相關交易總額約300億美元。這一激增凸顯了中國作為早期癌症研究領先創新中心的地位日益提升，以及其與全球藥物研發網路日益緊密的融合。

主要成長要素

全球癌症研究正以前所未有的速度發展，目前全球已有超過1,000項臨床試驗正在進行中。這種快速成長反映了全球癌症負擔的日益加重，以及對更有效、更具標靶性且毒性更小的治療方法方案的迫切需求。隨著傳統化療方法逐漸接近臨床極限，製藥和生物技術公司正增加對抗體藥物複合體（ADC）和雙特異性ADC等先進治療方法的投資。這些創新治療方法旨在更精準地靶向癌細胞，同時最大限度地減少對健康組織的損傷，已成為現代癌症藥物研發的核心。

新機會的趨勢

新一代技術正成為推動抗體藥物複合體（ADC）市場未來成長的關鍵趨勢。業界日益關注新一代藥物偶聯物（NGDC），它們代表著對第一代和第二代ADC設計的重大革新。這些先進治療方法的研發旨在解決傳統ADC的局限性，特別是脫靶毒性、循環穩定性不足以及治療反應的個體差異。隨著癌症治療領域對更精準、更安全治療方法的需求不斷成長，NGDC正處於標靶癌症治療關鍵創新領域的前沿。

最佳化障礙

藥物價格和高昂的治療費用在塑造當前抗體藥物複合體（ADC）市場的患者需求方面起著決定性作用。儘管ADC療法是目前最先進、臨床療效最佳的癌症治療方法之一，但其廣泛應用受到各醫療體系經濟限制的嚴重限制。 ADC生產的複雜性，加上高度專業化的生技藥品的研發和嚴格的監管要求，導致了高昂的價格結構，限制了患者獲得治療的機會，尤其是在對成本敏感的市場。

產業價值鏈分析
產業展望
- 全球靶向腫瘤學和抗體偶聯藥物（ADC）治療行業概覽
- 管道擴建、核准/許可/併購活動
- 下一代有效載荷、連接子和雙特異性ADC的創新
PESTLE分析
波特五力分析
市場成長及前景
- 2020-2035年市場收入估算與預測
- 價格趨勢分析：依產品分類

第4章：全球抗體藥物複合體（ADC）市場分析

競爭對手儀表板
- 市場集中度
- 企業市場占有率分析，2025 年
- 競爭對手分析與基準測試

第5章：全球抗體藥物複合體（ADC）市場分析

市場動態和趨勢
- 成長要素
- 抑制因子
- 機會
- 主要趨勢
市場規模及預測，2020-2035年
- 依產品
  - 關鍵見解
    - Kadcyla
    - Enhertu
    - Adcetris
    - Padcev
    - Trodelvy
    - Polivy
    - Blenrep
    - 其他
- 透過標靶抗原
  - 關鍵見解
    - HER2
    - CD30
    - TROP-2
    - CD22
    - Nectin-4
    - BCMA
    - 其他
- 有效載荷/技術
  - 關鍵見解
    - 奧瑞他汀（MMAE/MMAF）
    - 美登素類化合物（DM1/DM4）
    - KariCare縫紉機
    - 拓樸異構酶抑制劑（DXd）
    - 其他
- 連接器類型
  - 關鍵見解
    - 可切割的可切割
    - 非切割型非切割型
- 適應症
  - 關鍵見解
    - 乳癌
    - 血液疾病/血液癌症
    - 肺癌
    - 膀胱癌/尿路上皮癌
    - 卵巢癌
    - 其他
- 最終用戶
  - 關鍵見解
    - 醫院
    - 專科醫療/癌症中心
    - 其他
- 按地區
  - 關鍵見解
    - 北美洲
      - 美國
      - 加拿大
      - 墨西哥
    - 歐洲
      - 西歐
        
        英國
        德國
        法國
        義大利
        西班牙
        其他西歐國家
      - 東歐
        
        波蘭
        俄羅斯
        其他東歐國家
    - 亞太地區
      - 中國
      - 印度
      - 日本
      - 澳洲和紐西蘭
      - 韓國
      - ASEAN
      - 其他亞太國家
    - 中東和非洲（MEA）
      - 沙烏地阿拉伯
      - 南非
      - UAE
      - 其他中東和非洲國家
    - 南美洲
      - 阿根廷
      - 巴西
      - 其他南美國家

第6章：北美市場分析

第7章：歐洲市場分析

第8章：亞太市場分析

第9章：中東和非洲市場分析

第10章：南美市場分析

第11章：公司簡介

Zai Lab Ltd.
WuXi XDC
Takeda Pharmaceutical Co. Ltd
Synaffix BV
RemeGen Co., Ltd
Pfizer Inc.（Seagen Inc.）
Mersana Therapeutics Inc.
MacroGenics Inc.
Lonza Group AG
ImmunoGen Inc.
GSK plc
Gilead Sciences Inc.
Genmab A/S
F. Hoffmann-La Roche Ltd
Daiichi Sankyo Co. Ltd
Catalent Inc.
Bristol-Myers Squibb Co.
BioNTech SE
BeiGene Ltd.
AstraZeneca plc
Astellas Pharma Inc.
Amgen Inc.
ADC Therapeutics SA
AbbVie Inc.
Other Prominent Players

第12章附錄

簡介目錄

Product Code: AA06261828

The global antibody-drug conjugates (ADC) market is experiencing a period of significant expansion, reflecting the rapid transformation of oncology treatment toward more precise and targeted therapeutic approaches. In 2025, the market is valued at approximately USD 14.23 billion, and it is projected to reach around USD 45.39 billion by 2035. This growth represents a compound annual growth rate (CAGR) of 12.30% during the forecast period from 2026 to 2035, highlighting the strong and sustained momentum behind ADC adoption across global healthcare systems.

This robust growth trajectory is primarily driven by the broader shift toward precision oncology, which emphasizes the use of targeted biologic therapies designed to attack cancer cells with high specificity while minimizing damage to healthy tissues. ADCs have emerged as one of the most promising modalities within this framework due to their ability to combine the targeting precision of monoclonal antibodies with the potent cell-killing effects of cytotoxic payloads. This dual mechanism of action has significantly improved treatment outcomes in multiple cancer indications, leading to wider clinical acceptance and increased integration into standard oncology treatment protocols.

Noteworthy Market Developments

The competitive landscape of the antibody-drug conjugate (ADC) market is increasingly defined by large-scale mergers, acquisitions, and strategic licensing agreements, reflecting the intense race to secure leadership in next-generation oncology therapeutics. As demand for highly targeted cancer treatments continues to grow, major pharmaceutical companies are investing aggressively in ADC platforms to strengthen their oncology pipelines, expand technological capabilities, and gain access to commercially validated assets.

One of the most significant transactions in this space was the acquisition of Seagen by Pfizer for approximately $43 billion. This landmark deal was driven by Pfizer's strategic objective to strengthen its position in oncology and gain access to Seagen's pioneering ADC technology and established commercial portfolio.

Similarly, AbbVie made a major strategic move by acquiring ImmunoGen for approximately $10.1 billion. This acquisition provided AbbVie with access to the ADC therapy Elahere, a key asset in the treatment of ovarian cancer. Another notable transaction involved Johnson & Johnson, which acquired Ambrx Biopharma for approximately $2 billion.

Beyond acquisitions, China has emerged as a major force in global ADC deal-making and licensing activity. In 2024, Chinese biopharmaceutical companies secured a record 94 out-licensing agreements for innovative drug candidates, with the total value of oncology-related deals reaching approximately $30 billion. This surge highlights China's growing role as a key innovation hub in early-stage oncology research and its increasing integration into global pharmaceutical development networks.

Core Growth Drivers

Global oncology research is expanding at an unprecedented pace, with more than 1,000 active clinical trials currently underway worldwide. This rapid growth reflects the escalating global burden of cancer and the urgent need for more effective, targeted, and less toxic treatment options. As traditional chemotherapy approaches reach their clinical limitations, pharmaceutical companies and biotechnology firms are increasingly investing in advanced modalities such as antibody-drug conjugates (ADCs) and bispecific ADCs. These innovative therapies are designed to improve the precision targeting of cancer cells while minimizing harm to healthy tissue, making them a central focus of modern oncology drug development.

Emerging Opportunity Trends

Next-generation technology is emerging as a major opportunity trend driving future growth in the antibody-drug conjugate (ADC) market. The industry is increasingly shifting its focus toward next-generation drug conjugates (NGDCs), which represent a significant evolution beyond first- and second-generation ADC designs. These advanced therapies are being developed to address the limitations of earlier ADC formats, particularly challenges related to off-target toxicity, suboptimal stability in circulation, and variability in therapeutic response. As oncology continues to demand more precise and safer treatment options, NGDCs are positioned as a critical innovation frontier within targeted cancer therapy.

Barriers to Optimization

Drug pricing and the high cost of treatment play a decisive role in shaping current patient demand within the antibody-drug conjugate (ADC) market. While ADC therapies represent some of the most advanced and clinically effective cancer treatments available today, their widespread adoption is significantly influenced by affordability constraints across different healthcare systems. The complexity of ADC manufacturing, combined with highly specialized biologics development and strict regulatory requirements, contributes to elevated pricing structures that can limit access, particularly in cost-sensitive markets.

Detailed Market Segmentation

By target antigen, the HER2 segment maintains a commanding and highly influential position in the antibody-drug conjugate (ADC) market, accounting for approximately 48.60% of the total share as of 2025. This dominant standing reflects the strong clinical and commercial success of HER2-targeted therapies, which have fundamentally reshaped treatment approaches in oncology. The HER2 receptor, being overexpressed in a significant subset of breast and other solid tumors, has emerged as one of the most validated and therapeutically actionable targets in modern cancer treatment, making it a central focus of ADC development.

Within the complex payload technology landscape of the antibody-drug conjugate (ADC) market, calicheamicins hold a leading position, accounting for approximately 38.40% of the total market share. This dominance is largely driven by their exceptionally high cytotoxic potency, which makes them highly effective even at extremely low, sub-picomolar concentrations. As one of the most powerful classes of DNA-targeting payloads used in oncology, calicheamicins are specifically designed to induce irreversible double-strand breaks in cancer cell DNA, ultimately triggering cell cycle arrest and apoptosis. Their ability to deliver such targeted and lethal damage has made them a cornerstone in the development of several clinically successful ADC therapies.

By linker type, cleavable linkers hold the leading position in the antibody-drug conjugate (ADC) market, accounting for approximately 56.20% of the total share. This dominance is primarily attributed to their advanced biochemical design, which enables controlled drug release within the targeted tumor microenvironment. Cleavable linkers are engineered to remain stable in systemic circulation but to break down under specific intracellular conditions, such as changes in pH or the presence of particular enzymes. This selective activation mechanism enhances the therapeutic precision of ADCs while improving their overall clinical effectiveness.

By indication, breast cancer continues to maintain a dominant position in the antibody-drug conjugate (ADC) market, accounting for an overwhelming 62.30% share. This strong leadership reflects the high clinical need for more precise and effective targeted therapies in breast oncology, particularly for patients with advanced, metastatic, or treatment-resistant disease. The significant concentration of market share in this indication highlights how breast cancer has become the primary therapeutic focus for ADC development and commercialization within the oncology landscape.

Segment Breakdown

By Product

Kadcyla
Enhertu
Adcetris
Padcev
Trodelvy
Polivy
Blenrep
Others

By Target Antigen

HER2
CD30
TROP-2
CD22
Nectin-4
BCMA
Others

By Payload / Technology

Auristatins (MMAE / MMAF)
Maytansinoids (DM1 / DM4)
Calicheamicins
Topoisomerase Inhibitors (DXd)
Others

By Linker Type

Cleavable
Non-Cleavable

By Indication

Breast Cancer
Hematologic / Blood Cancers
Lung Cancer
Bladder / Urothelial Cancer
Ovarian Cancer
Others

By End User

Hospitals
Specialty & Cancer Centers
Others

By Region

North America
The U.S.
Canada
Mexico
Europe
Western Europe
The UK
Germany
France
Italy
Spain
Rest of Western Europe
Eastern Europe
Poland
Russia
Rest of Eastern Europe
Asia Pacific
China
India
Japan
Australia & New Zealand
South Korea
ASEAN
Rest of Asia Pacific
Middle East & Africa (MEA)
Saudi Arabia
South Africa
UAE
Rest of MEA
South America
Argentina
Brazil
Rest of South America

Geography Breakdown

North America holds the leading position in the global antibody-drug conjugate (ADC) market, supported by its highly advanced clinical infrastructure, substantial biopharmaceutical investment base, and extensive regulatory expertise. The region, particularly the United States, benefits from a well-established ecosystem that enables rapid translation of oncology research into commercially available therapies. Strong collaboration between academic research institutions, biotechnology companies, and large pharmaceutical firms has further strengthened its leadership in the development and commercialization of next-generation cancer treatments.
A major contributor to this dominance is the role of the U.S. Food and Drug Administration, which has approved a significant share of commercially available ADC therapies. The agency's structured yet innovation-supportive regulatory framework has enabled earlier patient access to breakthrough oncology medicines while maintaining rigorous safety and efficacy standards. This has positioned the United States as a key launch market for advanced ADC treatments, accelerating adoption across major cancer indications and reinforcing North America's leadership in this therapeutic segment.

Leading Market Participants

Zai Lab Ltd.
WuXi XDC
Takeda Pharmaceutical Co. Ltd
Synaffix BV
RemeGen Co., Ltd
Pfizer Inc. (Seagen Inc.)
Mersana Therapeutics Inc.
MacroGenics Inc.
Lonza Group AG
ImmunoGen Inc.
GSK plc
Gilead Sciences Inc.
Genmab A/S
F. Hoffmann-La Roche Ltd
Daiichi Sankyo Co. Ltd
Catalent Inc.
Bristol-Myers Squibb Co.
BioNTech SE
BeiGene Ltd.
AstraZeneca plc
Astellas Pharma Inc.
Amgen Inc.
ADC Therapeutics SA
AbbVie Inc.
Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global Antibody-Drug Conjugate (ADC) Market

Chapter 2. Research Methodology & Research Framework

2.1. Research Objective
2.2. Product Overview
2.3. Market Segmentation
2.4. Qualitative Research
- 2.4.1. Primary & Secondary Sources
2.5. Quantitative Research
- 2.5.1. Primary & Secondary Sources
2.6. Breakdown of Primary Research Respondents, By Region
2.7. Assumption for Study
2.8. Market Size Estimation
2.9. Data Triangulation

Chapter 3. Global Antibody-Drug Conjugate (ADC) Market Overview

3.1. Industry Value Chain Analysis
- 3.1.1. Antibody, Payload & Linker Component Suppliers
- 3.1.2. ADC Bioconjugation & Contract Manufacturers (CDMOs)
- 3.1.3. ADC Drug Developers & Biopharma Companies
- 3.1.4. Regulatory, Distribution & Specialty Pharmacy Channels
- 3.1.5. Healthcare Providers (Hospitals, Cancer Centers) & Patients
3.2. Industry Outlook
- 3.2.1. Overview of the Global Targeted Oncology & ADC Therapeutics Industry
- 3.2.2. Pipeline Expansion, Approvals & Licensing / M&A Activity
- 3.2.3. Next-Generation Payloads, Linkers & Bispecific ADC Innovation
3.3. PESTLE Analysis
3.4. Porter's Five Forces Analysis
- 3.4.1. Bargaining Power of Suppliers
- 3.4.2. Bargaining Power of Buyers
- 3.4.3. Threat of Substitutes
- 3.4.4. Threat of New Entrants
- 3.4.5. Degree of Competition
3.5. Market Growth and Outlook
- 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
- 3.5.2. Price Trend Analysis, By Product

Chapter 4. Global Antibody-Drug Conjugate (ADC) Market Analysis

4.1. Competition Dashboard
- 4.1.1. Market Concentration Rate
- 4.1.2. Company Market Share Analysis (Value %), 2025
- 4.1.3. Competitor Mapping & Benchmarking

Chapter 5. Global Antibody-Drug Conjugate (ADC) Market Analysis

5.1. Market Dynamics and Trends
- 5.1.1. Growth Drivers
- 5.1.2. Restraints
- 5.1.3. Opportunity
- 5.1.4. Key Trends
5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 5.2.1. By Product
  - 5.2.1.1. Key Insights
    - 5.2.1.1.1. Kadcyla
    - 5.2.1.1.2. Enhertu
    - 5.2.1.1.3. Adcetris
    - 5.2.1.1.4. Padcev
    - 5.2.1.1.5. Trodelvy
    - 5.2.1.1.6. Polivy
    - 5.2.1.1.7. Blenrep
    - 5.2.1.1.8. Others
- 5.2.2. By Target Antigen
  - 5.2.2.1. Key Insights
    - 5.2.2.1.1. HER2
    - 5.2.2.1.2. CD30
    - 5.2.2.1.3. TROP-2
    - 5.2.2.1.4. CD22
    - 5.2.2.1.5. Nectin-4
    - 5.2.2.1.6. BCMA
    - 5.2.2.1.7. Others
- 5.2.3. By Payload / Technology
  - 5.2.3.1. Key Insights
    - 5.2.3.1.1. Auristatins (MMAE / MMAF)
    - 5.2.3.1.2. Maytansinoids (DM1 / DM4)
    - 5.2.3.1.3. Calicheamicins
    - 5.2.3.1.4. Topoisomerase Inhibitors (DXd)
    - 5.2.3.1.5. Others
- 5.2.4. By Linker Type
  - 5.2.4.1. Key Insights
    - 5.2.4.1.1. Cleavable
    - 5.2.4.1.2. Non-Cleavable
- 5.2.5. By Indication
  - 5.2.5.1. Key Insights
    - 5.2.5.1.1. Breast Cancer
    - 5.2.5.1.2. Hematologic / Blood Cancers
    - 5.2.5.1.3. Lung Cancer
    - 5.2.5.1.4. Bladder / Urothelial Cancer
    - 5.2.5.1.5. Ovarian Cancer
    - 5.2.5.1.6. Others
- 5.2.6. By End User
  - 5.2.6.1. Key Insights
    - 5.2.6.1.1. Hospitals
    - 5.2.6.1.2. Specialty & Cancer Centers
    - 5.2.6.1.3. Others
- 5.2.7. By Region
  - 5.2.7.1. Key Insights
    - 5.2.7.1.1. North America
      - 5.2.7.1.1.1. The U.S.
      - 5.2.7.1.1.2. Canada
      - 5.2.7.1.1.3. Mexico
    - 5.2.7.1.2. Europe
      - 5.2.7.1.2.1. Western Europe
        
        5.2.7.1.2.1.1. The UK
        5.2.7.1.2.1.2. Germany
        5.2.7.1.2.1.3. France
        5.2.7.1.2.1.4. Italy
        5.2.7.1.2.1.5. Spain
        5.2.7.1.2.1.6. Rest of Western Europe
      - 5.2.7.1.2.2. Eastern Europe
        
        5.2.7.1.2.2.1. Poland
        5.2.7.1.2.2.2. Russia
        5.2.7.1.2.2.3. Rest of Eastern Europe
    - 5.2.7.1.3. Asia Pacific
      - 5.2.7.1.3.1. China
      - 5.2.7.1.3.2. India
      - 5.2.7.1.3.3. Japan
      - 5.2.7.1.3.4. Australia & New Zealand
      - 5.2.7.1.3.5. South Korea
      - 5.2.7.1.3.6. ASEAN
      - 5.2.7.1.3.7. Rest of Asia Pacific
    - 5.2.7.1.4. Middle East & Africa (MEA)
      - 5.2.7.1.4.1. Saudi Arabia
      - 5.2.7.1.4.2. South Africa
      - 5.2.7.1.4.3. UAE
      - 5.2.7.1.4.4. Rest of MEA
    - 5.2.7.1.5. South America
      - 5.2.7.1.5.1. Argentina
      - 5.2.7.1.5.2. Brazil
      - 5.2.7.1.5.3. Rest of South America

Chapter 6. North America Market Analysis

6.1. Market Dynamics and Trends
- 6.1.1. Growth Drivers
- 6.1.2. Restraints
- 6.1.3. Opportunity
- 6.1.4. Key Trends
6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 6.2.1. Key Insights
  - 6.2.1.1. By Product
  - 6.2.1.2. By Target Antigen
  - 6.2.1.3. By Payload / Technology
  - 6.2.1.4. By Linker Type
  - 6.2.1.5. By Indication
  - 6.2.1.6. By End User
  - 6.2.1.7. By Country

Chapter 7. Europe Market Analysis

7.1. Market Dynamics and Trends
- 7.1.1. Growth Drivers
- 7.1.2. Restraints
- 7.1.3. Opportunity
- 7.1.4. Key Trends
7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 7.2.1. Key Insights
  - 7.2.1.1. By Product
  - 7.2.1.2. By Target Antigen
  - 7.2.1.3. By Payload / Technology
  - 7.2.1.4. By Linker Type
  - 7.2.1.5. By Indication
  - 7.2.1.6. By End User
  - 7.2.1.7. By Country

Chapter 8. Asia Pacific Market Analysis

8.1. Market Dynamics and Trends
- 8.1.1. Growth Drivers
- 8.1.2. Restraints
- 8.1.3. Opportunity
- 8.1.4. Key Trends
8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 8.2.1. Key Insights
  - 8.2.1.1. By Product
  - 8.2.1.2. By Target Antigen
  - 8.2.1.3. By Payload / Technology
  - 8.2.1.4. By Linker Type
  - 8.2.1.5. By Indication
  - 8.2.1.6. By End User
  - 8.2.1.7. By Country

Chapter 9. Middle East & Africa Market Analysis

9.1. Market Dynamics and Trends
- 9.1.1. Growth Drivers
- 9.1.2. Restraints
- 9.1.3. Opportunity
- 9.1.4. Key Trends
9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 9.2.1. Key Insights
  - 9.2.1.1. By Product
  - 9.2.1.2. By Target Antigen
  - 9.2.1.3. By Payload / Technology
  - 9.2.1.4. By Linker Type
  - 9.2.1.5. By Indication
  - 9.2.1.6. By End User
  - 9.2.1.7. By Country

Chapter 10. South America Market Analysis

10.1. Market Dynamics and Trends
- 10.1.1. Growth Drivers
- 10.1.2. Restraints
- 10.1.3. Opportunity
- 10.1.4. Key Trends
10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
- 10.2.1. Key Insights
  - 10.2.1.1. By Product
  - 10.2.1.2. By Target Antigen
  - 10.2.1.3. By Payload / Technology
  - 10.2.1.4. By Linker Type
  - 10.2.1.5. By Indication
  - 10.2.1.6. By End User
  - 10.2.1.7. By Country